Varenzin-CA1 - Molidustat Oral Suspension for Cat Anemia Treatment (25mg/ml, 27ml)

FIRST-OF-ITS-KIND ORAL ANEMIA TREATMENT FOR CATS

Product Description

Varenzin-CA1 is a novel oral medication developed to treat anemia in cats associated with chronic kidney disease. This easy-to-administer liquid helps stimulate a cat’s body to produce its own red blood cells, supporting oxygen delivery and daily vitality. Developed specifically for cats and approved through FDA’s conditional pathway, it offers at-home convenience without injections and fits into ongoing CKD care plans.

Please note that the product may arrive in a Hardy Paw Pharmacy vial, manufacturer packaging is shown for reference.

Benefits

• Oral Convenience: Daily oral suspension that avoids clinic visits and painful injections.
• Targeted Anemia Support: Designed specifically to help control nonregenerative anemia in cats with CKD.
• Stimulates EPO Naturally: Encourages a cat’s body to increase its own erythropoietin for red blood cell production.
• At-Home Use: Simple dosing with an included syringe for easy administration by pet owners.

Variants

27 mL bottle of 25 mg/mL oral suspension.

Ingredients

Active Ingredients

Molidustat sodium (25 mg per mL).

Inactive Ingredients

Glycerol dibehenate, fish oil, sunflower oil, butylhydroxytoluene, and sorbic acid.

How to Use

Recommended-Dosage Chart

H4: Dosage & Administration Instructions

• Shake Well: Shake thoroughly before every dose to ensure the suspension is evenly mixed.
• Use Provided Syringe: Measure each dose only with the enclosed syringe for accurate administration.
• Round Up Dose: Round the calculated dose up to the nearest 0.1 mL increment.
• Oral Administration: Administer directly into the cat’s mouth once daily for up to 28 days.
• No Redosing: Do not re-dose if vomiting occurs after administration that day.
• Treatment Cycles: Allow at least a 7-day pause before repeating another treatment cycle.
• Prescription Only: Federal law restricts use to licensed veterinarians or their order.

Disclaimer: This dosage information is provided by the manufacturer. Always consult your veterinarian before administering or adjusting any supplement for your pet.

Additional Information

Precautions

• Risk of Thromboembolism: Use with care in cats that are already at risk for blood clots.
• History of Seizures: Be cautious when giving this to cats that have had seizures in the past.
• Breeding and Nursing Cats: Do not use in cats that are pregnant, nursing, or intended for breeding.
• Check Hematocrit Levels: Monitor HCT or PCV regularly to make sure levels do not rise too high.
• Spacing With Minerals: Give this medication at least one hour apart from phosphate binders or iron supplements.

Possible Side Effects

• Vomiting: This was the side effect reported most often during clinical studies.
• Higher Blood Pressure: Some patients experienced an increase in systolic blood pressure while on treatment.
• Elevated Potassium Levels: Mild and temporary rises in potassium levels were noted in some cases.
• Thromboembolic Event: A rare but serious case of suspected thromboembolism was reported during the field study.
• Seizures: A small number of cases reported seizure activity during the studies.

Storage Information

• Controlled Temperature: Store at 20°C to 25°C for optimal stability.
• Permitted Excursions: Temperature excursions allowed between 15°C and 30°C.
• Secure Storage: Keep bottle tightly closed and out of reach of children and animals.

Shipping & Return

We offer ground, express, priority, and international delivery; see our shipping policy for details.

For return instructions or product concerns, please refer to our detailed refund policy.

Prescription items are NON-RETURNABLE and NON-REFUNDABLE.

Frequently Asked Questions

Q1: What is Varenzin-CA1 used for in cats?

Ans: Varenzin-CA1 is prescribed to treat nonregenerative anemia in cats with chronic kidney disease. It helps the body produce more of its own erythropoietin, which stimulates the formation of red blood cells. The medication has conditional approval from the FDA while full effectiveness data are still being completed.

Q2: How does Varenzin-CA1 work in cats with CKD?

Ans: Varenzin-CA1 contains molidustat, which belongs to a class of drugs called hypoxia inducible factor prolyl hydroxylase inhibitors. It works by blocking HIF PH, which helps stabilize hypoxia inducible factor. As a result, the body produces more of its own erythropoietin. This increase supports red blood cell production and helps manage anemia linked to chronic kidney disease.

Q3: How is Varenzin-CA1 administered to cats?

Ans: Varenzin-CA1 is administered by mouth once per day at a dosage of 5 mg per kilogram of body weight for a treatment period of up to 28 straight days. The bottle should be shaken well before use, and the provided dosing syringe must be used to measure and administer the correct volume.

Q4: What are the possible side effects of Varenzin-CA1?

Ans: The most frequently reported adverse reaction in clinical studies was vomiting. Other observed effects included increases in systolic blood pressure and mild, transient increases in serum potassium. Rare but serious events such as suspected thromboembolism and seizures were also reported.

Q5: Can Varenzin-CA1 be used in pregnant or breeding cats?

Ans: Varenzin-CA1 should not be administered to pregnant, lactating, or breeding cats. Developmental toxicity findings in laboratory studies raise safety concerns, and the safe use of this product has not been established in these populations.